SmithKline Beecham said that currency exchange had a negative impact of12% on its pretax profits in the second quarter of 1997, and the effect on earnings per share was a negative of 13%. However, it stressed the strength of its underlying growth, which seemed to please investors; the firm's share price advanced 49 pence to L12.20 ($20.58) in the initial market reaction to the interim figures.
Second-quarter pretax profits were L356 million ($581 million), which reflected an advance of 4%, or 16% excluding currency. EPS was 8.4 pence, up 1% or 14% excluding currency fluctuations. Trading profit was L377 million, rising 2%, or 14% without the currency impact.
SB experienced a decline in group sales in the quarter of 1% to L1.9 billion, although they rose 8% when stripped of the currency effect. The company said that pharmaceutical products increased 15% in the quarter, while turnover of consumer health care products advanced 14%.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze